Gain Therapeutics (NASDAQ:GANX – Get Free Report) and Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.
Valuation & Earnings
This table compares Gain Therapeutics and Spyre Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gain Therapeutics | $50,000.00 | 1,509.94 | -$20.16 million | ($0.50) | -3.46 |
| Spyre Therapeutics | $890,000.00 | 8,796.96 | -$155.20 million | ($1.95) | -45.66 |
Insider & Institutional Ownership
12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Gain Therapeutics and Spyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gain Therapeutics | N/A | -161.59% | -118.36% |
| Spyre Therapeutics | N/A | -30.74% | -22.23% |
Volatility & Risk
Gain Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.99, indicating that its stock price is 199% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Gain Therapeutics and Spyre Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gain Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Spyre Therapeutics | 1 | 1 | 12 | 1 | 2.87 |
Gain Therapeutics currently has a consensus target price of $7.50, suggesting a potential upside of 333.53%. Spyre Therapeutics has a consensus target price of $109.69, suggesting a potential upside of 23.21%. Given Gain Therapeutics’ higher probable upside, equities analysts plainly believe Gain Therapeutics is more favorable than Spyre Therapeutics.
Summary
Spyre Therapeutics beats Gain Therapeutics on 10 of the 14 factors compared between the two stocks.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
About Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
